Selecting breast cancer treatment depends on the expression of the estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor type 2 (HER2); however, there are instances of subtype discordance between primary and metastatic lesions [1]. This evidence concerns the gene PGR and breast carcinoma.